Maria Lopez Case Study: Clinical Management of Generalized Anxiety Disorder

Patient Profile and Initial Presentation

  • Patient Name: Maria Lopez.
  • Age: 34 years old34\text{ years old}.
  • Gender: Female.
  • Ethnicity: Hispanic.
  • Occupation: Elementary school teacher.
  • Marital Status: Married.
  • Living Situation: Lives with husband and two children, ages 66 and 44.
  • Chief Complaint: "I just feel constantly anxious and on edge. I can't relax anymore."

History of Present Illness (HPI)

  • Duration: The patient reports worsening anxiety for the past 6 months6\text{ months}.
  • Symptom Characteristics:
    • Characterized by excessive worry occurring nearly every day.
    • Associated symptoms include restlessness, fatigue, muscle tension, difficulty concentrating, and insomnia (difficulty falling or staying asleep).
  • Triggers: The patient cannot pinpoint anything specific in her life causing the anxiety; there are no new significant life stressors.
  • Impact on Functioning: Symptoms interfere significantly with both work and family life.
  • Review of Systems (Constitutional/Psychiatric):
    • Positive findings: Anxiety, fatigue, muscle tension, and insomnia.
    • Negative findings: Denial of panic attacks, suicidal ideation (SI), homicidal ideation (HI), hallucinations, and delusions.
    • Negative for weight loss, chest pain, and shortness of breath.
    • Psychosomatic considerations: The patient denies heart palpitations, tingling in hands, or shortness of breath (symptoms typically indicative of panic).

Standardized Assessment Scores

  • Generalized Anxiety Disorder-7 (GAD-7): The patient scored 1515.
  • Patient Health Questionnaire-9 (PHQ-9): The patient scored 66.
  • Interpretation: A score of 1515 on the GAD-7 suggests severe anxiety. A score of 66 on the PHQ-9 suggests mild depressive symptoms, which often overlap with anxiety disorders.

Medical and Family History

  • Past Medical History (PMH): Significant for hypothyroidism.
  • Current Medications:
    • Levothyroxine: 75μg75\,\mu g daily.
    • Multivitamin: Once daily.
  • Allergies: No known medication allergies.
  • Family History:
    • Mother: History of depression.
    • Sister: History of anxiety.
  • Social History:
    • Alcohol Use: Drinks 2 glasses of wine2\text{ glasses of wine} on weekends.
    • Tobacco/Illicit Drug Use: Denies use.
    • Exercise: Currently does not exercise.
    • Safety: Feels safe at home.

Differential Diagnoses

  • Generalized Anxiety Disorder (GAD): Primary diagnosis based on the persistence and nature of symptoms for over 6 months6\text{ months}.
  • Panic Disorder: Considered due to psychosomatic complaints common in anxiety, though ruled out by the patient's denial of specific panic attack symptoms.
  • Hypothyroidism/Hyperthyroidism (Medication-Induced): Investigating if current levothyroxine levels are too high, causing iatrogenic hyperthyroidism (anxiety-mimicking symptoms).
  • Mild Depressive Disorder: Suggested by the subthreshold PHQ-9 score.
  • Adjustment Disorder with Anxiety: Considered if a trigger were present, though less likely as the patient denies specific stressors.
  • Cardiac Event: Rule out based on lack of chest pain or palpitations.

Diagnostic and Laboratory Plan

  • Thyroid Stimulating Hormone (TSH): Necessary to check stability on levothyroxine, ideally with reflex to Free T3 and T4.
  • Complete Blood Count (CBC): To screen for anemia or infection contributing to fatigue.
  • Comprehensive Metabolic Panel (CMP): To assess kidney and liver function and electrolyte balance.
  • Electrocardiogram (EKG): Discussed but deemed unnecessary for this specific patient due to the absence of cardiac risk factors or clinical symptoms like palpitations or chest pain.
  • Pregnancy Test: Recommended for women of childbearing age before starting certain medications, depending on contraceptive use.
  • Gastrointestinal Assessment: Importance of assessing the "gut-brain axis" by asking about nausea, vomiting, or changes in bowel movements.

Therapeutic Plan: Non-Pharmacological Interventions

  • Cognitive Behavioral Therapy (CBT): The most research-backed counseling approach in conjunction with medication. A referral should be provided.
  • Sleep Hygiene: Essential due to reported insomnia; focus on regular schedules and environments.
  • Exercise: Recommend small, manageable goals (e.g., 5 minutes5\text{ minutes} outside) to improve mood and reduce anxiety.
  • Lifestyle Modifications: Limit caffeine intake and reduce alcohol consumption.
  • Mindfulness: Practice deep breathing exercises and identifying triggers.
  • Safety Planning/Support Network: Identifying resources and people to contact during high-stress periods to ensure the patient does not feel alone.

Therapeutic Plan: Pharmacological Management

  • Selective Serotonin Reuptake Inhibitors (SSRIs): First-line therapy.
    • Sertraline (Zoloft): Start at a low dose of 25mg25\,mg.
    • Escitalopram (Lexapro): Recommended dose of 10mg10\,mg, potentially starting at 5mg5\,mg for the first week.
  • Side Effects to Monitor: Nausea, diarrhea, insomnia, and initial feelings of "dysregulation."
  • Treatment Timeline:
    • Initial response takes 2 to 4 weeks2\text{ to }4\text{ weeks}.
    • Full therapeutic effect occurs at 4 to 6 weeks4\text{ to }6\text{ weeks} (sometimes up to 8 weeks8\text{ weeks}).
  • Benzodiazepines (e.g., Xanax, Ativan): Not recommended for general anxiety disorder due to risk of dependence and difficulty with withdrawal. May be used very short-term (bridge therapy) but generally avoided as they are not first-line.
  • Alternatives for Crisis/Sleep: Hydroxyzine or Propranolol (the latter for physical symptoms like palpitations).

Physical Examination Findings

  • Constitutional: Patient is alert and cooperative.
  • Psychiatric: Patient appears mildly anxious. Mood is recorded as "anxious." Affect is congruent with mood.
  • Cardiovascular: Heart sounds S1 and S2 present with no murmurs, gallops, or rubs.
  • Respiratory: Lungs clear to auscultation bilaterally.

Follow-up and Compliance

  • Follow-up Interval: Reassess in 4 to 6 weeks4\text{ to }6\text{ weeks} to evaluate the effectiveness of medication and labs.
  • Prescription Dosing: Provide only a 30-day supply30\text{-day supply} initially to ensure the patient returns for follow-up and to mitigate risks of overdose in patients with depressive symptoms.
  • Patient Education:
    • Normalize anxiety as a treatable condition to reduce stigma.
    • Stress the importance of adherence; do not stop medication abruptly to avoid rebound anxiety or neurological withdrawal symptoms.
    • Tapering off may be considered after approximately 6 months6\text{ months} of symptom stability.

Questions & Discussion

  • Patient Red Red Flags: Questions were raised regarding suicidal ideation (SI), homicidal ideation (HI), and psychosis. These must always be assessed.
  • Diagnostic Redundancy: Discussion of avoiding repetitive questioning during Objective Structured Clinical Examinations (OSCEs) by separating the HPI and Review of Systems (ROS) effectively.
  • Clinical Hours Tracking: Mention of clinical hour reports via systems like Trellis and Exact.
  • SANE Training: Discussion regarding 40 clinical hours40\text{ clinical hours} for Sexual Assault Nurse Examiner (SANE) training being used toward clinical requirements.
  • Preceptor Coordination: Clarification on designating a main preceptor in systems like Exact when working at sites with multiple providers (e.g., Healthtopia).